James C. Clemmer - Jul 7, 2022 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role
President and CEO, Director
Signature
/s/ Richard C.Rosenzweig, as Attorney in Fact
Stock symbol
ANGO
Transactions as of
Jul 7, 2022
Transactions value $
-$176,110
Form type
4
Date filed
7/11/2022, 06:08 AM
Previous filing
Jan 12, 2022
Next filing
Jul 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANGO Common Stock Options Exercise $0 +25.1K +6.43% $0.00 416K Jul 7, 2022 Direct F1
transaction ANGO Common Stock Tax liability -$176K -8.57K -2.06% $20.54 407K Jul 7, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANGO Performance Right Options Exercise $0 -50.1K -100% $0.00* 0 Jul 7, 2022 Common Stock 50.1K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This acquisition of 25,123 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019
F2 The exempt disposition of 8,574 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.
F3 On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 25,123 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.